Webinar: Risk-Sharing Agreements in the U.S.: Trends, Barriers & Prospects
On November 16, 2015, Kimberly Westrich, MA, vice president, health services research, National Pharmaceutical Council (NPC) moderated the webinar. She kicked off the conversation by noting that there is great interest in risk-sharing agreements (RSAs) as a way to address challenges in the current health care environment.
She also introduced the webinar speakers, who included:
- Josh Carlson, PhD, assistant professor, University of Washington School of Pharmacy, who provided an overview of the taxonomy and current landscape for RSAs, along with some examples of RSAs in the United States;
- Lou Garrison, PhD, professor, University of Washington School of Pharmacy, who who presented interview findings and survey results from the research study, "Private Sector Risk-Sharing Agreements in the U.S.: Trends, Barriers and Prospects"; and
- Ed Pezalla, PhD, vice president, pharmacy policy and strategy, Aetna, who shared how payers view elements of performance-based contracts.
Видео Webinar: Risk-Sharing Agreements in the U.S.: Trends, Barriers & Prospects канала npcnow
She also introduced the webinar speakers, who included:
- Josh Carlson, PhD, assistant professor, University of Washington School of Pharmacy, who provided an overview of the taxonomy and current landscape for RSAs, along with some examples of RSAs in the United States;
- Lou Garrison, PhD, professor, University of Washington School of Pharmacy, who who presented interview findings and survey results from the research study, "Private Sector Risk-Sharing Agreements in the U.S.: Trends, Barriers and Prospects"; and
- Ed Pezalla, PhD, vice president, pharmacy policy and strategy, Aetna, who shared how payers view elements of performance-based contracts.
Видео Webinar: Risk-Sharing Agreements in the U.S.: Trends, Barriers & Prospects канала npcnow
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Risk-Sharing Agreements in the US: Trends, Barriers and Prospects](https://i.ytimg.com/vi/vVLFNNWaEOQ/default.jpg)
![CER, Heterogeneity, and Cost Considerations](https://i.ytimg.com/vi/xwP4G7WQ5H0/default.jpg)
![NPC Webinar: Findings from Annual Survey of Health Care Stakeholders](https://i.ytimg.com/vi/ai_flOJ7LKk/default.jpg)
![Factors Affecting Patient Responses to Therapies](https://i.ytimg.com/vi/2Caa8BmeBEI/default.jpg)
![Why Real-World Evidence Matters](https://i.ytimg.com/vi/R-GCip4Jtd0/default.jpg)
![Current Challenges in Comparative Effectiveness Research](https://i.ytimg.com/vi/E7yZTRqbZb8/default.jpg)
![Individual Treatment Effects and Randomized Controlled Trials](https://i.ytimg.com/vi/Mtei0RjLtBs/default.jpg)
![Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment](https://i.ytimg.com/vi/WZK68sft-Vw/default.jpg)
![FDA's Dr Temple: How Could the Pharma Industry Respond to CER Findings?](https://i.ytimg.com/vi/xcgUgdvevpo/default.jpg)
![FDA Use of Big Data in Modeling and Simulations](https://i.ytimg.com/vi/jBxm1qU8nVw/default.jpg)
![The Evidence Needs of Payers](https://i.ytimg.com/vi/eEBV458_qZ4/default.jpg)
![Anthem's Dr. Malin on Care Pathways: Their Implementation and Evaluation](https://i.ytimg.com/vi/qvFkCGlfVvw/default.jpg)
![Understanding the Concept of Heterogeneity](https://i.ytimg.com/vi/eKGBvB7r5nI/default.jpg)
![How Do Payers Consider and Value Evidence in Decision-Making?](https://i.ytimg.com/vi/2cJvXUrrOPU/default.jpg)
![Achieving Quality in Accountable Care Organizations](https://i.ytimg.com/vi/jpJa-nFo2Iw/default.jpg)
![Kimberly Westrich, MA, Vice President for Health Services Research, National Pharmaceutical Council](https://i.ytimg.com/vi/bYZvf56x-eU/default.jpg)
![Shifting the Focus From "How Much" to "How Well" We Spend Our Health Care Dollars](https://i.ytimg.com/vi/jYynaj4wa1c/default.jpg)
![CMS' High-Value Principles on Quality Measures](https://i.ytimg.com/vi/Zi2eR-_mDA8/default.jpg)
![Getting Patients Engaged in Comparative Effectiveness Research](https://i.ytimg.com/vi/3GUhQZgO9JU/default.jpg)
![FDA Moving Data to the Cloud, Data Mining Social Media](https://i.ytimg.com/vi/qmCGLFgAdXc/default.jpg)
![A Pharmaceutical Industry View on Standards to Govern Communication](https://i.ytimg.com/vi/V6gTIrFhbFo/default.jpg)